Weizhen Qiao1, Jian Zou1, Fengfeng Ping1, Zhenge Han2, Lingling Li1, Xiuzhi Wang3. 1. Center of Clinical Research, Wuxi Institute of Translational Medicine, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China. 2. Department of Clinical Laboratory, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 200052, China. 3. Institute of Medical and Technology, Xuzhou Medical University, Xuzhou 221004, China.
Abstract
BACKGROUND: This study aimed to analyze the distribution and prophylaxis strategy of pathogens causing fungal infection in lung transplant recipients from cardiac-brain dead donors in the perioperative period to provide evidence for antifungal prophylaxis and treatment in lung transplant recipients. METHODS: This retrospective study evaluated 194 lung transplant recipients from January 2015 to December 2016. Fungal pathogens were isolated and identified from respiratory tract cultures before and after transplantation in the perioperative period. The galactomannan (GM) testing of bronchoalveolar lavage fluid (BALF) might facilitate the diagnosis of Aspergillus infection. Data were statistically analyzed using SPSS 19.0. RESULTS: A total of 31 cases of fungal strains isolated from the 194 recipients were identified prior to lung transplantation, and the positive rate was 16.0% (31/194). A total of 27 cases of isolated fungal strains in the 194 recipients were identified, and the positive rate after lung transplantation was 13.9% (27/194) in the perioperative period. A total of 54 cases with positive fungal infection (27.8%) were detected before and after lung transplantation. Overall, 10.3% (20/194) of the lung transplant recipients developed fungal infection in the observation period. The most common fungal pathogens were filamentous fungi and Candida albicans. CONCLUSIONS: Our data suggested that fungi were frequently isolated before and after transplantation from respiratory samples. However, the incidence of invasive fungal infection in lung transplant recipients in the perioperative period was relatively low. Targeted antifungal prophylaxis and treatment should be applied on the basis of the fungal distribution status of different individuals.
BACKGROUND: This study aimed to analyze the distribution and prophylaxis strategy of pathogens causing fungal infection in lung transplant recipients from cardiac-brain dead donors in the perioperative period to provide evidence for antifungal prophylaxis and treatment in lung transplant recipients. METHODS: This retrospective study evaluated 194 lung transplant recipients from January 2015 to December 2016. Fungal pathogens were isolated and identified from respiratory tract cultures before and after transplantation in the perioperative period. The galactomannan (GM) testing of bronchoalveolar lavage fluid (BALF) might facilitate the diagnosis of Aspergillus infection. Data were statistically analyzed using SPSS 19.0. RESULTS: A total of 31 cases of fungal strains isolated from the 194 recipients were identified prior to lung transplantation, and the positive rate was 16.0% (31/194). A total of 27 cases of isolated fungal strains in the 194 recipients were identified, and the positive rate after lung transplantation was 13.9% (27/194) in the perioperative period. A total of 54 cases with positive fungal infection (27.8%) were detected before and after lung transplantation. Overall, 10.3% (20/194) of the lung transplant recipients developed fungal infection in the observation period. The most common fungal pathogens were filamentous fungi and Candida albicans. CONCLUSIONS: Our data suggested that fungi were frequently isolated before and after transplantation from respiratory samples. However, the incidence of invasive fungal infection in lung transplant recipients in the perioperative period was relatively low. Targeted antifungal prophylaxis and treatment should be applied on the basis of the fungal distribution status of different individuals.
Entities:
Keywords:
Lung transplantation; fungal; infection; perioperative period
Authors: S S Weigt; R M Elashoff; C Huang; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; M P Keane; R Saggar; J P Lynch; D A Zisman; D J Ross; J A Belperio Journal: Am J Transplant Date: 2009-05-13 Impact factor: 8.086
Authors: Me-Linh Luong; Cornelius J Clancy; Aniket Vadnerkar; Eun Jeong Kwak; Fernanda P Silveira; Mark C Wissel; Kevin J Grantham; Ryan K Shields; Maria Crespo; Joseph Pilewski; Yoshiya Toyoda; Steven B Kleiboeker; Diana Pakstis; Sushruth K Reddy; Thomas J Walsh; M Hong Nguyen Journal: Clin Infect Dis Date: 2011-05 Impact factor: 9.079
Authors: Pearlie P Chong; Cassie C Kennedy; Matthew A Hathcock; Walter K Kremers; Raymund R Razonable Journal: Clin Transplant Date: 2015-02-12 Impact factor: 2.863
Authors: S Shalhoub; M-L Luong; S J Howard; S Richardson; L G Singer; C Chaparro; S Keshavjee; Y Akinlolu; C Rotstein; T Mazzulli; S Husain Journal: J Antimicrob Chemother Date: 2015-01-20 Impact factor: 5.790
Authors: Shahid Husain; Martha L Mooney; Lara Danziger-Isakov; Frauke Mattner; Nina Singh; Robin Avery; Michael Ison; Atul Humar; Robert F Padera; Leo P Lawler; Andy Fisher; Richard J Drew; Kate F Gould; Amparo Sole; Sean Studer; Patricia Munoz; Lianne G Singer; Margaret Hannan Journal: J Heart Lung Transplant Date: 2011-04 Impact factor: 10.247